William Blair Investment Management LLC Makes New $1.98 Million Investment in Boston Scientific Corporation $BSX

Key Points

• William Blair Investment Management initiated a Boston Scientific position worth approximately $1.98 million by purchasing 46,375 shares in the second quarter. Institutional investors own 89.07% of the company.
• Boston Scientific reported quarterly EPS of $0.86, beating estimates by $0.03, while revenue rose 7.5% year over year to $5.44 billion. The company also authorized a $5 billion share buyback, covering up to 6.4% of outstanding shares.
• Analysts maintain a generally positive outlook, with 24 Buy ratings and a consensus “Moderate Buy” rating, despite multiple price-target reductions. The average analyst target is $71.62, compared with shares recently trading near $50.39.

William Blair Investment Management LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 46,375 shares of the medical equipment provider's stock, valued at approximately $1,979,000.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth about $26,000. Main Street Financial Solutions LLC raised its position in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock valued at $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its position in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock valued at $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock valued at $763,000 after acquiring an additional 2,556 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.0%

Shares of NYSE BSX opened at $50.39 on Monday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The firm has a 50-day simple moving average of $46.34 and a two-hundred day simple moving average of $57.62. The company has a market cap of $73.03 billion, a P/E ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig bought 5,000 shares of the firm's stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on BSX shares. Citigroup reduced their price objective on Boston Scientific from $70.00 to $61.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Needham & Company LLC cut their target price on Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a research report on Wednesday, July 8th. Raymond James Financial restated an "outperform" rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Finally, BTIG Research lowered their price target on Boston Scientific from $65.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source